

CLAIMS

1) Anti-allergic pharmaceutical composition containing at least two active agents chosen among : (i) one allergen, (ii) one antihistamine compound, (iii) one inhibitor of histamine synthesis, said active agents being  
5 associated in said composition with a pharmaceutically acceptable vehicle.

2) Anti-allergic pharmaceutical composition according to claim 1, containing (i) at least one allergen and (ii)  
10 at least one antihistamine compound, and optionally (iii) at least one inhibitor of histamine synthesis, in a pharmaceutically acceptable vehicle.

3) Anti-allergic pharmaceutical composition according  
15 any of claims 1 or 2, characterized in that it contains (i) at least one allergen and (ii) at least one antihistamine compound, in a pharmaceutically acceptable vehicle, enabling release of the peptides and other chemical substances in independent manner at galenic  
20 level.

4) Pharmaceutical composition according to any of claims 1 to 3, characterized in that the allergen is chosen from among the major antigens or mixture of major  
25 antigens of acarids able to induce an immune reaction.

5) Pharmaceutical composition according to any of claims 1 to 4, characterized in that the allergen is a major antigen of *D. Pteronyssinus* and/or *D. Farinae*.

5       6) Pharmaceutical composition according to any of claims 1 to 5, characterized in that the allergen is a cystine protease.

10      7) Pharmaceutical composition according to any of the preceding claims, characterized in that the allergen is at least a peptide epitope of a cystine protease.

15      8) Pharmaceutical composition according to any of the preceding claims, characterized in that the allergen is at least a peptide epitope of a cystine protease whose amino acid sequence is chosen from among SEQ ID NO : 1 and SEQ ID NO : 2 in the list of appended sequences.

20      9) Pharmaceutical composition according to any of the preceding claims, characterized in that the allergen is a peptide or mixture of peptides chosen from the group comprising the peptides of sequences SEQ ID NO : 3, SEQ ID NO : 4, SEQ ID NO : 5 in the list of appended sequences.

25      10) Pharmaceutical composition according to any of the preceding claims, characterized in that the antihistamine compound is chosen from the group comprising: brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxizine,

ketotifene, loratadine, mequitazine, oxotomide,  
mizolastine, ebastine, astemizole, carbinoxamide,  
alimemazine, buclizine, cyclizine hydrochlorate,  
doxylamine.

5

11) Anti-allergic pharmaceutical composition according any of claims 1 or 2, characterized in that it contains at least one antihistamine compound and at least one inhibitor of histamine synthesis, said compounds being associated in said composition with a pharmaceutically acceptable vehicle.

10

12) Pharmaceutical composition according to claim 11, characterized in that the inhibitor of histamine synthesis is an inhibitor of histidine decarboxylase.

15

13) Pharmaceutical composition according to claim 12, characterized in that the inhibitor of histidine decarboxylase is tritoqualine.

20

14) Pharmaceutical composition according to any of claims 1 to 10, characterized in that it contains a quantity of allergen of the order of 1 to 1500 µg, and advantageously from 10 to 150 µg.

25

15) Pharmaceutical composition according to any of the preceding claims, characterized in that it contains a quantity of antihistamine compound of the order of 1 to 2000 mg, and advantageously from 5 to 200 mg.

16) Pharmaceutical composition according to any of claims 1 to 15, characterized in that it contains an inhibitor of histamine synthesis.

5

17) Pharmaceutical composition according to claim 16, characterized in that it contains a quantity of inhibitor of histamine synthesis of between 1 and 2000 mg.

10 18) Pharmaceutical composition according any of claims 11 to 13, characterized in that it contains from 5 to 200 mg of an antihistamine compound and from 10 to 300 mg of an inhibitor of histidine decarboxylase such as tritoqualine.

15

19) Pharmaceutical composition according to any of claims 1 to 10 or 14, characterized in that it comprises a nucleotide primer sequence SEQ ID NO : 6 in the list of appended sequences including an epigenic sequence of the major protein of the acarid, in lieu and stead of the composition containing the major protein of the acarid.

20) Pharmaceutical composition according to any of claims 1 to 10 or 14 or 19, characterized in that it comprises a nucleotide primer sequence according to sequence SEQ ID NO : 6 in the list of appended sequences including an epigenic sequence of at least one epitope of the major allergen of the acarid in lieu and stead of the composition containing the major protein of the acarid.

- 21) Pharmaceutical composition according to claim 20,  
characterized in that it comprises nucleotide primer  
sequences according to sequence SEQ ID NO : 6 in the list  
5 of appended sequences including in alternate manner at  
least two epigenic sequences of at least one epitope of  
the major allergen of the acarid in lieu and stead of the  
composition containing the major protein of the acarid.
- 10 22) Pharmaceutical composition according to any of  
claims 1 to 10 or 14, characterized in that it comprises a  
nucleotide primer sequence SEQ ID NO : 7 in the list of  
appended sequences including an epigenic sequence of the  
major protein of the acarid, in lieu and stead of the  
15 composition containing the major protein of the acarid.
- 20 23) Pharmaceutical composition according to any of  
claims 1 to 10 or 14 or 22, characterized in that it  
comprises a nucleotide primer sequence according to  
sequence SEQ ID NO : 7 in the list of appended sequences  
including an epigenic sequence of at least one epitope of  
the major allergen of the acarid in lieu and stead of the  
composition containing the major protein of the acarid.
- 25 24) Pharmaceutical composition according to claim 23,  
characterized in that it comprises nucleotide primer  
sequences according to sequence SEQ ID NO : 7 in the list  
of appended sequences including in alternate manner at  
least two epigenic sequences of at least one epitope of

the major allergen of the acarid in lieu and stead of the composition containing the major protein of the acarid.

25) Pharmaceutical composition according to any of  
5 claims 1 to 10 or 14, characterized in that it comprises  
an RNA sequence enabling the coding of the major protein  
of the acarid in lieu and stead of the composition  
containing the major protein of the acarid.

10 26) Pharmaceutical composition according to any of  
the preceding claims, characterized in that it permits the  
TH2/TH1 switch and reduction of the allergic reaction both  
on the upstream phase (IgE synthesis) and on the  
downstream phase (synthesis and release of histamine).

15 27) Pharmaceutical composition according to any of  
the preceding claims, characterized in that it is released  
in the form of a transcutaneous patch to allow better  
access of the allergens used and/or their epitopes to the  
20 antigen-presenting cells.

28) Pharmaceutical composition according to any of  
the preceding claims characterized in that it is released  
in mucosal, eye lotion, nasal spray or bronchial form.

25 29) Pharmaceutical composition according to any of  
the preceding claims characterized in that it is released  
in a galenical form with programmed mucosal or sublingual  
and secondarily *per os* disintegration.

30) Pharmaceutical composition according to any of  
the preceding claims for the preparation of a medicinal  
product intended to treat or prevent allergic  
5 hypersensitive reactions.

31) Pharmaceutical composition according to any of  
the preceding claims for the preparation of a medicinal  
product intended to treat or prevent allergic asthma,  
10 allergic rhinitis, atopic and allergic eczema.

32) Pharmaceutical composition according to any of  
the preceding claims for the preparation of a medicinal  
product intended to treat or prevent allergic symptoms in  
15 children, infants and adults.

RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE  
APR 10 1997